(Q37924323)

25 August 2017

1 reference

title

Pharmacogenetics and pharmacogenomics of thienopyridines: clinically relevant? (English)

1 reference

25 August 2017

1 reference

Sandra L Close

1

1 reference

25 August 2017

publication date

31 August 2011

1 reference

Fundamental and Clinical Pharmacology

25 August 2017

published in

1 reference

25 August 2017

volume

26

1 reference

25 August 2017

issue

1

1 reference

25 August 2017

page(s)

19-26

1 reference

ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non–ST-Elevation Myocardial Infarction

25 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2011.00983.X

2009 Focused Updates: ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction (updating the 2004 Guideline and 2007 Focused Update) and ACC/AHA/SCAI Guidelines on Percutaneous Coronary Intervention (updating the 200

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2011.00983.X

Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2011.00983.X

Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2011.00983.X

Clopidogrel response variability and future therapies: clopidogrel: does one size fit all?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2011.00983.X

Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2011.00983.X

Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2011.00983.X

Clopidogrel non-responsiveness and risk of cardiovascular morbidity. An updated meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2011.00983.X

Prasugrel versus clopidogrel in patients with acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2011.00983.X

Increased active metabolite formation explains the greater platelet inhibition with prasugrel compared to high-dose clopidogrel

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2011.00983.X

Metabolism and disposition of the thienopyridine antiplatelet drugs ticlopidine, clopidogrel, and prasugrel in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2011.00983.X

Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2011.00983.X

Interactions of two major metabolites of prasugrel, a thienopyridine antiplatelet agent, with the cytochromes P450.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2011.00983.X

The disposition of prasugrel, a novel thienopyridine, in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2011.00983.X

The biotransformation of prasugrel, a new thienopyridine prodrug, by the human carboxylesterases 1 and 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2011.00983.X

Population pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel in aspirin-treated patients with stable coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2011.00983.X

Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2011.00983.X

Cytochrome p-450 polymorphisms and response to clopidogrel

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2011.00983.X

A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2011.00983.X

Clinical consequences of cytochrome P450 2C9 polymorphisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2011.00983.X

Genetic polymorphism of cytochrome P450 2C19 in Mexican Americans: a cross-ethnic comparative study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2011.00983.X

Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2011.00983.X

Genetic variation of CYP2C19 affects both pharmacokinetic and pharmacodynamic responses to clopidogrel but not prasugrel in aspirin-treated patients with coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2011.00983.X

Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2011.00983.X

Besides CYP2C19*2, the variant allele CYP2C9*3 is associated with higher on-clopidogrel platelet reactivity in patients on dual antiplatelet therapy undergoing elective coronary stent implantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2011.00983.X

Lack of association between the P2Y12 receptor gene polymorphism and platelet response to clopidogrel in patients with coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2011.00983.X

Increased risk of atherothrombotic events associated with cytochrome P450 3A5 polymorphism in patients taking clopidogrel

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2011.00983.X

CYP2C19*2 and CYP2C9*3 alleles are associated with stent thrombosis: a case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2011.00983.X

Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2011.00983.X

The pharmacogenetics and pharmacodynamics of clopidogrel response: an analysis from the PRINC (Plavix Response in Coronary Intervention) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2011.00983.X

Cytochrome P450 2C19 loss-of-function polymorphism, but not CYP3A4 IVS10 + 12G/A and P2Y12 T744C polymorphisms, is associated with response variability to dual antiplatelet treatment in high-risk vascular patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2011.00983.X

Relation of cytochrome P450 2C19 loss-of-function polymorphism to occurrence of drug-eluting coronary stent thrombosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2011.00983.X

The cytochrome 2C19*2 and *3 alleles attenuate response to clopidogrel similarly in East Asian patients undergoing elective percutaneous coronary intervention.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2011.00983.X

Carriage of cytochrome 2C19 polymorphism is associated with risk of high post-treatment platelet reactivity on high maintenance-dose clopidogrel of 150 mg/day: results of the ACCEL-DOUBLE (Accelerated Platelet Inhibition by a Double Dose of Clopidog

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2011.00983.X

Impact of CYP2C19 polymorphisms on the antiplatelet effect of clopidogrel in an actual clinical setting in Japan.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2011.00983.X

Pre-Procedural Platelet Reactivity After Clopidogrel Loading in Korean Patients Undergoing Scheduled Percutaneous Coronary Intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2011.00983.X

Genetic determinants of response to clopidogrel and cardiovascular events

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2011.00983.X

Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2011.00983.X

Cytochrome P450 2C19 loss-of-function polymorphism and stent thrombosis following percutaneous coronary intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2011.00983.X

Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2011.00983.X

Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2011.00983.X

Cytochrome P450 2C19*2 polymorphism and cardiovascular recurrences in patients taking clopidogrel: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2011.00983.X

Cardiovascular risk in clopidogrel-treated patients according to cytochrome P450 2C19*2 loss-of-function allele or proton pump inhibitor coadministration: a systematic meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2011.00983.X

Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2011.00983.X

Effects of CYP2C19 genotype on outcomes of clopidogrel treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2011.00983.X

Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2011.00983.X

Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2011.00983.X

Interaction between clopidogrel and proton-pump inhibitors and management strategies in patients with cardiovascular diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2011.00983.X

Impact of cytochrome P450 2C19 loss-of-function polymorphism and of major demographic characteristics on residual platelet function after loading and maintenance treatment with clopidogrel in patients undergoing elective coronary stent placement

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2011.00983.X

10.1111/J.1472-8206.2011.00983.X

21 January 2018

Identifiers

DOI

1 reference

25 August 2017

1 reference